Life
Exploring New Frontiers in Biotech: CAR-T and GSK's Strategic Shift
Recent developments in biotech highlight the potential of CAR-T therapies in treating autoimmune diseases, alongside GSK's decision to phase out leucovorin.
editorial-staff
1 min read
Updated about 14 hours ago
Summary
The biotech landscape is witnessing significant changes, particularly with the emerging promise of CAR-T therapies in the realm of autoimmunity.
In a strategic move, GSK has announced its departure from the leucovorin market, signaling a shift in its focus within the pharmaceutical sector.
These developments reflect broader trends in the industry, as biotech companies adapt to new challenges and opportunities.
Key Facts
- Key facts pending editorial review.
Updates
- No subsequent updates recorded.